A Homogenous PBMC ADCC Bioassay Enables Bridging Studies with ADCC Reporter Bioassays in Immunotherapy Monoclonal Antibody Development

Part # PS369


Pete Stecha, Julia Gilden, Jun Wang, Denise Garvin, Jim Hartnett, Frank Fan, Mei Cong and Zhijie Jey Cheng
Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711

Antibody-dependent cellular cytotoxicity (ADCC) is a key mechanism of action for therapeutic antibodies. Previously, we developed a surrogate ADCC Reporter Bioassay using engineered reporter effector cells and demonstrated its suitability for antibody product release and stability study. Here we describe an improved ADCC assay using PBMC and engineered HiBiT-target cells for use in antibody early characterization and to enable ADCC method bridging studies.

Printed in USA.